Welcome to our dedicated page for Mineralys Therapeutics news (Ticker: MLYS), a resource for investors and traders seeking the latest updates and insights on Mineralys Therapeutics stock.
Mineralys Therapeutics, Inc. develops medicines for hypertension and related comorbidities driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for hypertension, chronic kidney disease, obstructive sleep apnea and other aldosterone-related conditions.
Mineralys news commonly covers lorundrostat clinical data, FDA regulatory updates, New Drug Application developments, and corporate updates tied to clinical and regulatory funding. Other recurring announcements include quarterly financial results, health care conference participation, executive appointments, and employee equity inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics, a clinical-stage biopharmaceutical company, has successfully closed its initial public offering (IPO) of 13,800,000 shares of common stock at an offering price of $16.00 per share. This IPO raised $220.8 million in gross proceeds, including the full exercise of the underwriters' option to purchase an additional 1,800,000 shares. The company's common stock is traded on the Nasdaq under the ticker symbol MLYS. The offering was managed by leading financial institutions, ensuring a robust market entry for Mineralys, focusing on treating diseases linked to elevated aldosterone levels.